NEW YORK — Dutch firm Vitestro announced Tuesday that it has raised $22 million to commercialize its robotic blood-drawing device.
The company has raised a total of $50 million from equity investments and grant funding, it said. In March 2023, Vitestro raised $12.9 million in a Series A financing round.
The current financing was led by Sonder Capital and new investor NYBC Ventures. Invest-NL, the European Innovation Council Fund, and existing private investors also participated in the financing round, which Vitestro said will go toward commercialization of its technology in Europe and the expansion of its operations into the US.
The firm's robotic blood-drawing device combines artificial intelligence, advanced imaging technology, and robotics for accurate and autonomous blood draws. The devices have been pre-ordered for use at several European hospitals at the end of the year, Utrecht, Netherlands-based Vitestro said.
"Vitestro's revolutionary device is perfectly positioned to improve patient care and streamline operations for a medical laboratory market in crisis," Fred Moll, managing partner at Sonder Capital and cofounder of Intuitive Surgical, said in a statement. "As turnover and departures accelerate, staff are overwhelmed, and labs are challenged to deliver timely test results and satisfactory care."